嘉晨西海生物技术有限公司创始人王子豪博士毕业于美国约翰霍普金斯大学，毕业后曾就职于多个国际大型制药企业长达 11 年之久，在职期间直接参与过四价流感、艾滋病、狂犬病、呼吸道合胞病毒、人巨细胞病毒等疫苗的 CMC 开发。

王子豪博士作为最早参与自复制 mRNA 工艺设计优化和产业化开发的人员之一，专注于 mRNA 技术平台的工艺开发8年，并且直接参与了 mRNA 技术平台在多个病毒传染病领域的有效性及安全性验证和临床开发等。

Dr. Zihao Wang is the Chief Executive Officer at Immorna and Co-founder of the Immorna family of companies. Dr. Wang is a seasoned entrepreneur and established biopharmaceutical veteran. He has over 14 years of biotech R&D and leadership experience. He is one of the pioneers in self-replicating mRNA (srRNA) CMC development and is the mastermind behind the development of the mRNA platform technologies at Immorna, which include an improved next generation srRNA, conventional mRNA, and circular RNA. Dr. Wang pioneers the application of srRNA-LNP against oncology indications.

Prior to founding the Immorna family of companies, Dr. Wang held various R&D roles at GSK Vaccines, Novartis Vaccines and Diagnostics, Grifols SA, etc. During his tenure at Novartis and GSK, he spent more than 7 years working directly on srRNA CMC development and the application of srRNA technology against various viral infectious diseases.

Dr. Wang is the lead author on more than 20 publications with more than 2000 citations. He is also the inventor on multiple patents related to mRNA design, RNA delivery, and their applications in various disease areas. Dr. Wang received his B.S. in Biochemistry from Fudan University in Shanghai, and his Ph.D. in Biological Chemistry from The Johns Hopkins University.